Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Catalent

Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.

Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply

Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)'s controlling shareholder was to buy the firm for US$16.5 billion. Novo Holdings, which owns a majority stake in the weight loss drug maker, unveiled the takeover on Monday, which includes assumed debt and, at US$63.50 a share, represents a 16.5% premium on Catalent's Friday closing price.

Catalent surges on $16.5 billion takeover by Novo Nordisk shareholder

The controlling shareholder of Wegovy maker Novo Nordisk is buying Catalent in a deal that values the U.S. drug company at $16.5 billion, including debt.

Wegovy Maker to Boost Production Capacity With Multibillion-Dollar Deal

Novo Nordisk's acquisition of three fill-finish sites will help boost output of its popular Wegovy and Ozempic drugs, the CEO of its parent company Novo Holdings said on Monday.

Fill-finish sites will help Novo Nordisk boost Wegovy, Ozempic output - Novo Holdings CEO

Novo Holdings will acquire Catalent for $63.50 a share in cash.

Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk

Novo Holdings, the holding company of Novo Nordisk , will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-loss drug Wegovy, the companies said on Monday.

Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity

Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's close. The deal is a 39% premium to Catalent's close before it announced a strategic review.

Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion

Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration.

Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction

COPENHAGEN, Denmark & SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an e.

Novo Holdings to Acquire Catalent

ASML Hld

Novartis

SAP SE

LVMH Moet Hennessy Louis Vuitton

Fourth-quarter earnings season in Europe is still in its early days, but the largest companies on the Continent are mostly hitting their stride.

It's shaping up to be a great quarter for Europe's biggest companies — no thanks to Europe.

Novo Nordisk is one of the pharmaceutical stocks of the moment. And it just delivered an estimate-busting earnings report.

Is Novo Nordisk a Hot Stock to Buy Now After its Spectacular Q4?

Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Novo Nordisk (NVO)

AbbVie

Eli Lilly

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.

4 Large Drug Stocks Trying to Survive the Industry Challenges

Broadcom

JPMorgan Chase & Co

“A billion here, a billion there, and pretty soon you're talking real money.” While a trillion-dollar price tag is likely more common in today's inflationary times, only a handful of companies have managed to attain that real-money status.

The Road to a Trillion: 3 Stocks Next in Line for the Mega Milestone

Novo Nordisk (NYSE:NVO) remains a buy for US bank Citigroup even though it is only the second European company in history to pass the half-a-trillion mark after LVMH temporarily hit the landmark last year. The Danish pharma accompanied its annual report with a management call that reiterated scaling up production of its blockbuster diabetes drugs Wegovy and Ozempic remains its number one priority.

Novo Nordisk still a buy for Citi as return on capital hits 88%

Novo Nordisk says it Is gradually ramping up supply of its sought-after drug Wegovy. However, the company is still warning patients demand will still outpace supply overall.

Novo Nordisk increasing supply of Wegovy as demand continues to grow

Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript

The drug maker vaulted ahead of luxury goods maker LVMH to claim the title of Europe's most valuable company.

Ozempic and Wegovy maker Novo Nordisk now worth $500B amid soaring popularity

The American depositary receipts (ADRs) of Novo Nordisk (NVO), the market leader in weight-loss drugs, rose sharply in early trading Wednesday, hitting an all-time high, after the Danish company said it expects sales growth this year of between 18% and 26% in constant exchange terms.

Novo Nordisk Stock Hits Record High as Wegovy Maker Sees Up To 26% Sales Growth This Year

Makers of Wegovy, Ozempic and Zepbound can't keep up with skyrocketing demand for their GLP-1 drugs, so insurance coverage isn't important for near-term growth.

Why Obesity Drug Coverage Doesn't Matter (Yet) for Lilly and Novo

Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales

The Danish company has started to increase the supply of lower-dose strengths of its blockbuster weight-loss drug, having limited supply in the U.S. since May to safeguard supplies.

Novo Nordisk Begins Gradually Increasing Supply of Wegovy

Novo Nordisk stock rose early Wednesday after the drugmaker beat fourth-quarter expectations, though weight-loss drug sales missed.

Novo Nordisk's Wegovy Comes In Light, But Ozempic Puts Up A Commanding Beat

Bagsværd, Denmark, 31 January 2024 – Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2022. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com.

Novo Nordisk files annual report with the SEC

Novo Nordisk will target launches of its mega popular obesity shot Wegovy in markets where it already has strong sales of its older weight-loss drug Saxenda, CEO Lars Fruergaard Jorgensen said, as it faces growing competition from U.S. rival Eli Lilly.

News for Novo Nordisk Stock (NVO)